Literature DB >> 1936808

HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis.

M P Manns1, A Bremm, P M Schneider, A Notghi, G Gerken, M Prager-Eberle, B Stradmann-Bellinghausen, K H Meyer zum Büschenfelde, C Rittner.   

Abstract

HLA class I, II, and III alleles were investigated in 25 consecutive unrelated German patients with primary biliary cirrhosis and in two families with two primary biliary cirrhosis patients in each. In primary biliary cirrhosis patients, HLA class I antigens did not differ significantly from in health controls. For HLA class II antigens, a highly significant increase of HLA DRw8 was found in patients with primary biliary cirrhosis compared with controls. Thirty-six percent vs. 3.6% were DRw8 positive [relative risk = 15.28; P (corrected) = 0.00013]. The genetic typing of HLA class III alleles revealed an increased incidence for C4AQ0 alleles [72% vs. 34.5%, relative risk = 4.89: P (corrected) = 0.0056]. A highly significant proportion of primary biliary cirrhosis patients carrying both DRw8 and C4A-Q0 alleles (relative risk = 183.75; P = 9.7 x 10(-7)) were found. In one family, a mother and her daughter had primary biliary cirrhosis, both sharing the major histocompatibility complex haplotype HLA-A1, -B8, -DR3, -C4AQ0B1. In the other family, two sisters with primary biliary cirrhosis shared the major histocompatibility complex haplotype HLA-A24, -B8, -DRw8, -C4A4B2. These studies contribute to the further elucidation of the immunogenetic background of primary biliary cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1936808     DOI: 10.1016/0016-5085(91)90090-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  20 in total

Review 1.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

Review 2.  Genetics and genomics of primary biliary cirrhosis.

Authors:  Brian D Juran; Konstantinos N Lazaridis
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

Review 3.  Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving.

Authors:  Pietro Invernizzi
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

4.  Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.

Authors:  Jennifer E Guy; Peiqing Qian; Jeffrey A Lowell; Marion G Peters
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

Review 5.  Prevalence and pattern of familial disease in primary biliary cirrhosis.

Authors:  A M Brind; G P Bray; B C Portmann; R Williams
Journal:  Gut       Date:  1995-04       Impact factor: 23.059

6.  Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese.

Authors:  Lie-Ying Fan; Xiao-Qing Tu; Ye Zhu; Thomas Pfeiffer; Ralph Feltens; Winfried Stoecker; Ren-Qian Zhong
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

7.  Distinctive HLA-II association with primary biliary cholangitis on the Island of Sardinia.

Authors:  Maria Grazia Clemente; Fulvia Frau; Matilde Bernasconi; Maria Doloretta Macis; Lucia Cicotto; Giampaolo Pilleri; Stefano De Virgiliis; Paolo Castiglia; Patrizia Farci
Journal:  United European Gastroenterol J       Date:  2016-08-09       Impact factor: 4.623

8.  HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility.

Authors:  P Donaldson; K Agarwal; A Craggs; W Craig; O James; D Jones
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

9.  Genomic variants associated with primary biliary cirrhosis.

Authors:  Carlo Selmi; Natalie J Torok; Andrea Affronti; M Eric Gershwin
Journal:  Genome Med       Date:  2010-01-26       Impact factor: 11.117

10.  Genetic basis of human complement C4A deficiency. Detection of a point mutation leading to nonexpression.

Authors:  G Barba; C Rittner; P M Schneider
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.